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ABSTRACT
A 35-year-old female dentist laid on her 
chair to test an N2O machine, and after 
only a few minutes of inhaling the N2O, 
she developed acute pyramidal syndrome. 
The patient started walking again eight 
months later, but still suffers from lower 
limb motor deficit, in spite of intensive re-
habilitation. Genetic tests later showed that 
the patient had Type 3 homocystinuria. 
This is the first case report of acute neu-
rological toxicity after brief administration 
of N2O. We suggest starting vitamin B12 
and folic acid supplements promptly in pa-
tients who experience neurological symp-
toms after receiving N2O. 
Key words: case report, neurological toxic-
ity, nitrous oxide, adverse reaction, homo-
cystinuria, dental care 
INTRODUCTION
A 35-year-old dentist, from Italy, breathed 
N2O for a few minutes, resulting in perma-
nent motor deficit, in spite of intensive re-
habilitation. Written consent has been ob-
tained from the patient to share her story. 
CASE REPORT
The patient is a young woman, of prior 
good health, who exercised regularly (run-
ning, skiing) and led an orderly life. In 
2001, the patient was hospitalized with 
vertigo and paresthesia in her right leg. 
An MRI was performed, uncovering a left 
fronto-parietal lesion, possibly second-
ary to a monophasic inflammatory pro-
cess. The etiology of the episode remained 
cryptic, with a temporal association to a 
flu shot received two days before the on-
set of symptoms. The episode completely 
resolved, resulting in no motor or mental 
deficits.
In 2010, the woman laid on her dentistry 
chair to test, on herself, an N2O machine 
she was about to buy. The technician from 
the company was administering the N2O, 
to prove the safety and ease of use of the 
machine. After only a few minutes, the 
dentist started experiencing neurological 
symptoms, which evolved into an acute 
right pyramidal syndrome, involving 
the entire right half of the body. After 20 
minutes, the patient was hospitalized and 
investigated for possible stroke. However, 
CT and MRI showed no changes from the 
previous examination, still describing the 
abovementioned fronto-parietal lesion.
The patient improved slightly after a few 
days, and after daily physiotherapy started 
walking again eight months later, but – as 
of today (6 years after the episode) – she 
still suffers from right lower limb motor 
deficit and ulnar nerve hypoesthesia, in 
spite of intensive rehabilitation and physi-
cal therapy.
Differential diagnosis included: equip-
ment failure (with delivery of a hypoxic 
mixture), air embolism (with concomitant 
right to left atrial shunt), pre-existing vi-
tamin B12 or folate deficiency, psychiatric 
disorder, autosomal recessive methylene 
tetrahydrofolate reductase (MTHFR) defi-
ciency or polymorphism. 
The N2O machine was tested to rule out 
malfunctioning and the occurrence of hy-
poxic flows, and was found to be working 
properly.
Air embolism associated with a patent fo-
ramen ovale was considered, since nitrous 
oxide expands existing gas bubbles which 
could then pass into the central nervous 
system. (1) However, echocardiography 
did not document a right to left shunt in 
our patient, and the patient had no source 
of air embolism (e.g. no intravenous line).
Pre-existing vitamin B12 or folate deficien-
cy has been associated with the occurrence 
of neurological events in nitrous oxide 
abusers, (2) but it has also been reported in 
patients who underwent single-time pro-
longed nitrous oxide anesthesia. (3) The 
patient did not have symptoms of vitamin 
B12 or folate deficiency before the “nitrous 
oxide incident” and the laboratory exams 
were completely normal upon hospital ad-
mission.
Psychiatric disorders (e.g. Munchausen 
syndrome) were ruled out.
Genetic tests were performed two years af-
ter the episode and showed that the patient 
had Type 3 homocystinuria due to a ho-
mozygote C677T mutation of the MTHFR 
gene. This mutation leaves approximately 
50% residual enzyme activity and marks 
enzyme lability to heat inactivation. (4) It 
is associated with a cytosine to thymine 
mutation at nucleotide position 677, en-
coding for an alanine-223 to valine sub-
stitution. This mutation is quite common, 
with a homozygote frequency up to 17% 
in the Caucasian population. Carrier fre-
quency may be as high as 40%. (4) 
The most plausible hypothesis is that ni-
trous oxide was the cause of the acute neu-
rological deficit.  It is possible, in fact, that 
the encephalitis triggered a neurological 
remodeling with the development of al-
ternate neural networks – which allowed 
the patient to have no clinical sequelae 
despite structural abnormalities. Nitrous 
oxide has many central effects mediated 
by N-methyl-D-aspartate (NMDA) re-
ceptors, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPA) 
receptors, neuronal nicotinic receptors, 
2-pore domain potassium channels, in-
volving adrenergic, gabaergic and opioi-
dergic pathways. (5) Therefore, it is not 
inconceivable that one of these actions 
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somehow interrupted the compensatory 
neural pathways she had developed.  This 
is, however, merely speculative, and has 
never been described previously.
DISCUSSION
Nitrous oxide is widely used as an analge-
sic-anesthetic drug. The large ENIGMA-
II trial (6) proved nitrous oxide as safe 
in patients known or suspected to have 
coronary artery disease undergoing major, 
non-cardiac surgery.
Because of its psychoactive properties, it is 
well-known for its abuse potential. Its side 
effects include limb numbness, formica-
tion and muscular weakness. Severe neu-
rological side effects have been observed 
in nitrous oxide abusers, with progressive 
demyelination and consequent axonal le-
sions of peripheral nerves. (7) A large 
questionnaire study, interviewing around 
35,000 dentists and assistants, demon-
strated that chronic professional exposure 
to nitrous oxide relates to polyneuropathy 
3-to-4-fold when compared to the general 
population. (8) Nonetheless, N2O is the 
most frequently used agent for sedation in 
dental procedures. 
Many studies demonstrated that N2O se-
lectively inhibits methionine synthase, a 
vitamin B12 dependent enzyme which 
plays a key role in the folate cycle. (9) The 
folate cycle is fundamental for the produc-
tion of DNA, myelin and catecholamines. 
When N2O is cleaved in azote and oxy-
gen, it causes vitamin B12 oxidation and 
therefore the impossibility for it to act as 
a coenzyme. Another key enzyme in the 
folate cycle is methylene tetrahydrofolate 
reductase (MTHFR). (9)
In the presence of a genetic deficit of 
MTHFR, a simultaneous iatrogenic im-
pairment of methionine synthase could re-
sult in a complete block of the folate cycle, 
with ill-fated effects on the production of 
myelin and DNA.
This is the first reported case of neuro-
logical damage triggered by a very short 
exposure to nitrous oxide in an adult pa-
tient. Notably, Selzer et al. (10) described 
the death of a child who underwent nitrous 
oxide anesthesia twice and was later diag-
nosed with MTHFR deficiency. The au-
topsy showed asymmetric cerebral atrophy 
and severe demyelination. 
Millions of patients are receiving nitrous 
oxide every year, not only for dental care, 
but also in general surgery. We suggest ni-
trous oxide not be given to patients with 
previous neurological insults. We also sug-
gest that patients with neurological insults 
after nitrous oxide administration receive 
immediate supplementation with vitamins 
and folic acid and undergo a MTHFR gene 
mutation analysis.  
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